24-Norursodeoxycholic acid
CAS No. 99697-24-2
24-Norursodeoxycholic acid( nor-UDCA )
Catalog No. M22919 CAS No. 99697-24-2
24-norursodeoxycholic acid is a side chain-shortened C23 homolog of UDCA.It has shown potent anti-inflammatory, anti-cholestatic, and anti-fibrotic properties.It is a Ursodeoxycholic Acid derivative. It is superior to Ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice24-norUrsodeoxycholic acid markedly improved liver tests and liver histology and significantly reduced hydroxyproline content and the number of infiltrating neutrophils and proliferating hepatocytes and cholangiocytes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 52 | In Stock |
|
| 10MG | 82 | In Stock |
|
| 25MG | 124 | In Stock |
|
| 50MG | 206 | In Stock |
|
| 100MG | 311 | In Stock |
|
| 200MG | 462 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name24-Norursodeoxycholic acid
-
NoteResearch use only, not for human use.
-
Brief Description24-norursodeoxycholic acid is a side chain-shortened C23 homolog of UDCA.It has shown potent anti-inflammatory, anti-cholestatic, and anti-fibrotic properties.It is a Ursodeoxycholic Acid derivative. It is superior to Ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice24-norUrsodeoxycholic acid markedly improved liver tests and liver histology and significantly reduced hydroxyproline content and the number of infiltrating neutrophils and proliferating hepatocytes and cholangiocytes.
-
Description24-norursodeoxycholic acid is a side chain-shortened C23 homolog of UDCA.It has shown potent anti-inflammatory, anti-cholestatic, and anti-fibrotic properties.It is a Ursodeoxycholic Acid derivative. It is superior to Ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice24-norUrsodeoxycholic acid markedly improved liver tests and liver histology and significantly reduced hydroxyproline content and the number of infiltrating neutrophils and proliferating hepatocytes and cholangiocytes. 24-norUrsodeoxycholic acid underwent extensive phase I/II metabolism (hydroxylation, sulfation, and glucuronidation), thereby increasing the hydrophilicity of biliary bile acid secretion. There was a coordinated induction of bile acid detoxifying enzymes (Cyp2b10, Cyp3a11, and Sult2a1) and efflux pumps (Mrp3 and Mrp4). Ursodeoxycholic acid, in contrast, increased alanine transaminase and alkaline phosphatase levels, had no significant effects on hydroxyproline content, and induced biliary transporters and detoxification enzymes to a much smaller extent than 24-norUrsodeoxycholic acid.
-
In Vitro24-norursodeoxycholic acid (Norucholic acid) is a side chain-shortened C23 homologue of UDCA and is previously shown to be highly effective in preclinical mouse models of cholestatic and fibrotic liver diseases. 24-norursodeoxycholic acid significantly reduces serum alkaline phosphatase (ALP) levels in a dose-dependent fashion. 24-norursodeoxycholic acid also significantly reduces γ-GT, ALT, and AST serum levels.
-
In Vivo——
-
Synonymsnor-UDCA
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number99697-24-2
-
Formula Weight378.55
-
Molecular FormulaC23H38O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (264.17 mM; Need ultrasonic)
-
SMILESC[C@H](CC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Fickert P, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2006 Feb;130(2):465-81.
molnova catalog
related products
-
Pomalidomide-PEG4-C-...
Pomalidomide-PEG4-C-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
-
GNF2133
GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.
-
BTB-1
BTB-1 is a novel small molecule inhibitor of the mitotic motor protein Kif18A.
Cart
sales@molnova.com